Company intelligence / Profile preview

RUTI Immunotherapeutics

Ownership: Private
Development stage: Phase 2

Overview

RUTI® has demonstrated good safety and immunogenicity in phase I and II trials for latent tuberculosis infection. It is currently being evaluated in phase IIb trials as an adjunct to chemotherapy for active and multidrug-resistant TB. Early-stage studies are ongoing or planned for other indications such as bladder cancer and allergic diseases[2][5][6][7][8].

Therapeutic areas: Infectious Diseases
Modalities: Inactivated vaccinePolyantigenic vaccineImmunostimulants
Industry: Biotech

Drug pipeline

2 assets

RUTI

Phase 2

Indications: Tuberculosis, Drug-resistant tuberculosis, Latent tuberculosis infection

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on RUTI Immunotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RUTI Immunotherapeutics.

Explore the full profile